Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Gauckler, P; Shin, JI; Alberici, F; Audard, V; Bruchfeld, A; Busch, M; Cheung, CK; Crnogorac, M; Delbarba, E; Eller, K; Faguer, S; Galesic, K; Griffin, S; Hrušková, Z; Jeyabalan, A; Karras, A; King, C; Kohli, HS; Maas, R; Mayer, G; Moiseev, S; Muto, M; Odler, B; Pepper, RJ; Quintana, LF; Radhakrishnan, J; Ramachandran, R; Salama, AD; Segelmark, M; Tesař, V; Wetzels, J; Willcocks, L; Windpessl, M; Zand, L; Zonozi, R; Kronbichler, A, ;RITERM, study, group;RITERM, study, group.
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
Autoimmun Rev. 2020; 19(11):102671
Doi: 10.1016/j.autrev.2020.102671
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Eller Kathrin
- Odler Balazs
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Primary forms of minimal change disease and focal segmental glomerulosclerosis are rare podocytopathies and clinically characterized by nephrotic syndrome. Glucocorticoids are the cornerstone of the initial immunosuppressive treatment in these two entities. Especially among adults with minimal change disease or focal segmental glomerulosclerosis, relapses, steroid dependence or resistance are common and necessitate re-initiation of steroids and other immunosuppressants. Effective steroid-sparing therapies and introduction of less toxic immunosuppressive agents are urgently needed to reduce undesirable side effects, in particular for patients whose disease course is complex. Rituximab, a B cell depleting monoclonal antibody, is increasingly used off-label in these circumstances, despite a low level of evidence for adult patients. Hence, critical questions concerning drug-safety, long-term efficacy and the optimal regimen for rituximab-treatment remain unanswered. Evidence in the form of large, multicenter studies and randomized controlled trials are urgently needed to overcome these limitations.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult - administration & dosage
- Glomerulosclerosis, Focal Segmental - drug therapy
- Humans - administration & dosage
- Immunologic Factors - therapeutic use
- Immunosuppressive Agents - adverse effects
- Nephrosis, Lipoid - drug therapy
- Nephrotic Syndrome - administration & dosage
- Recurrence - administration & dosage
- Rituximab - therapeutic use
- Find related publications in this database (Keywords)
- Nephrotic syndrome
- Rituximab
- Minimal change disease
- Focal segmental glomerulosclerosis
- Long-term remission
- Infections